Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HI MAN : Moderna says its vaccine for ages under 6 will be ready for U.S. review in June
https://www.cnbc.com/2022/05/01/moderna-says-its-vaccine-for-ages-under-6-will-be-ready-for-us-review-in-june.html?__source=sharebar|email&par=sharebar
2 Biotech Stocks to Buy and Hold for 10 Years:
https://www.fool.com/investing/2022/04/30/2-biotech-stocks-to-buy-and-hold-for-10-years/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
FDA Sets Review Dates For MODERNA:
The agency reserved June 8, 21, and 22 for virtual meetings of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) to review Moderna Inc
MONTREAL, April 29 - Canada is reviewing a request by Moderna to approve its COVID-19 vaccine for pediatric use in children aged 6 months to 5 years, the government and the company said on Friday.
Moderna's Canada General Manager Patricia Gauthier said at a news conference the request was filed with Canada Health on Thursday night.
Canada Health posted the application on its website on Friday and said it was under review.
Vaccines have been indiscriminately saving lives since 1796:
https://www.who.int/campaigns/world-immunization-week/2022
MODERNA FILES TO EXPAND CONDITIONAL MARKETING AUTHORIZATION FOR ITS COVID-19 VACCINE TO INCLUDE CHILDREN SIX MONTHS TO UNDER SIX YEARS IN THE EUROPEAN UNION
https://investors.modernatx.com/news/news-details/2022/Moderna-Files-to-Expand-Conditional-Marketing-Authorization-for-Its-COVID-19-Vaccine-to-Include-Children-Six-Months-to-Under-Six-Years-in-The-European-Union/default.aspx
Long lasting contracts with governments ahead$$$$$$$$$
MODERNA FINALIZES PLAN FOR LONG-TERM STRATEGIC PARTNERSHIP WITH THE GOVERNMENT OF CANADA
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
The ten-year strategic partnership is expected to provide Canadians with rapid response capabilities to ensure future pandemic readiness
https://investors.modernatx.com/news/news-details/2022/Moderna-Finalizes-Plan-for-Long-Term-Strategic-Partnership-with-The-Government-of-Canada/default.aspx
MODERNA FILES FOR AUTHORIZATION OF ITS COVID-19 VACCINE IN YOUNG CHILDREN SIX MONTHS TO UNDER SIX YEARS OF AGE
https://investors.modernatx.com/news/news-details/2022/Moderna-Files-for-Authorization-of-Its-COVID-19-Vaccine-in-Young-Children-Six-Months-to-Under-Six-Years-of-Age/default.aspx
The 12 cases in Israel occurred in the last four months, with five being hospitalized at Shaare Zedek Medical Center in Jerusalem and seven at Schneider Children’s Medical Center in Petah Tikva. Two of the children in Schneider had liver failure, requiring doctors to perform liver transplants. The other children’s conditions improved quickly after steroid treatment, and they were discharged from the hospitals.
11 of the 12 children had been infected with the coronavirus in the previous year. One hypothesis being tested is that liver inflammation is a symptom of long-term COVID.
https://medriva.com/mysterious-cases-of-severe-hepatitis-outbreaks-in-children-continue-to-rise-rise/#gs.yssidr
Arpa Garay Joins Moderna as Chief Commercial Officer:
During Ms. Garay's 16-year tenure at Merck, she gained broad international enterprise with increasing responsibility across oncology, vaccines, specialty, and chronic care. She consistently drove business growth in U.S. and international P&L roles, including leading mergers and acquisitions decisions and longer-term strategic choices, while building and inspiring diverse, talented teams. Prior to her role as Chief Marketing Officer, Ms. Garay served as President of Global Oncology and Digital at MSD (the tradename of Merck & Co., Inc.), where she led the commercialization of pipeline assets as well as business development for Merck's oncology portfolio, including alliances with Astra Zeneca, Eisai, and Seagen
cancer vaccine next!
https://www.accesswire.com/viewarticle.aspx?id=699004
The new era of vaccines!
Moderna has a solid pipeline covering a variety of therapeutic areas. And two potential blockbusters recently entered phase 3 studies: a cytomegalovirus (CMV) vaccine candidate and a respiratory syncytial virus (RSV) vaccine candidate.
money$$$$$$
very nice$$$$$$$$$
LOL: Good news though if you had Moderna primary series 2 shots—with a booster (either mRNA booster)— your VE stays much higher around 50-60% protection against symptomatic #Omicron even at 15-19 weeks post-booster. This is much better than AZ primary or Pfizer primary series.
8) And again, data from 🇬🇧 shows, have had a full Moderna 2 shot series is much stronger than 2 shots of Pfizer or AstraZeneca. The data shows it’s over and over again. It’s the vaccine that has the least relative waning against #Omicron. https://t.co/89PjC2UJfP
— Eric Feigl-Ding (@DrEricDing) April 23, 2022
Saudi Arabia approves Moderna vaccine for kids
https://www.timeoutriyadh.com/news/saudi-arabia-approves-moderna-vaccine-kids
fake news: will retire on July 8 David Meline, Moderna's current CFO, has decided to retire and will remain with the Company as a consultant to ensure a smooth transition of the CFO role to Mr. Gomez.
"I am very thankful to David for having decided to come out of retirement in the spring of 2020 to help us get Moderna ready for commercialization in record time. Moderna was an early-stage development, U.S. focused company when David joined us. He goes back into retirement after having helped transform Moderna into a global commercial company. He has built a great team and strong financial business processes. It has been a pleasure to work with him, and I wish him and his wife a wonderful time."
Mr. Gomez joins Moderna from Dentsply Sirona, Inc. (Nasdaq: XRAY)
"It is a privilege for me to join an organization that is focused on developing transformative medicines to address major public healthcare challenges worldwide," said Mr. Gomez. "I look forward to working with the team on this great mission."
https://investors.modernatx.com/news/news-details/2022/Jorge-Gomez-Joins-Moderna-as-Chief-Financial-Officer/default.aspx
Facing COVID Surge, China Revises Course To Support Imported mRNA Vaccines $MRNA
https://scrip.pharmaintelligence.informa.com/SC146150/Facing-COVID-Surge-China-Revises-Course-To-Support-Imported-mRNA-Vaccines
COVID and the Heart: It Spares No One:
https://publichealth.jhu.edu/2022/covid-and-the-heart-it-spares-no-one
$MRNA winner
8) And again, data from 🇬🇧 shows, have had a full Moderna 2 shot series is much stronger than 2 shots of Pfizer or AstraZeneca. The data shows it’s over and over again. It’s the vaccine that has the least relative waning against #Omicron. https://t.co/89PjC2UJfP
— Eric Feigl-Ding (@DrEricDing) April 23, 2022
Scientists urge China to replace its faltering Covid vaccines
China may have to overcome its reluctance to approve a foreign-made vaccine to tackle the latest outbreak, as well as rapidly rolling out boosters of its domestic shots. Otherwise, it will probably have to impose stricter — and costly — lockdowns to prevent a potentially huge death toll.
https://www.ft.com/content/729f1dc0-32d1-42c9-bb62-63a41f1e8de2
Moderna shares dropped as low as $17.91 in February 2020 as the pandemic began.
Shares of Moderna eventually peaked at $497.49 in August 2021 before pulling back.
everyone made money!!!!!!!!!!
https://www.benzinga.com/article/26674414
Moderna plans to submit an application to the U.S. health regulator for emergency use authorization (EUA) of its COVID-19 vaccine among kids between the ages of six months to five years by end of the month, a company spokesperson said on Wednesday.
The Omicron variant was predominant during Moderna's pediatric trial, and the drugmaker said two doses were around 38% effective in preventing infections in 2 to 5-year-olds and 44% effective for children aged 6 months to under 2 years.
Congratulations to TeamModerna for winning the Vaccine Industry Excellence award for Best New Vaccine Technology & Platform at the World Vaccine Congress!
Congratulations to #TeamModerna for winning the Vaccine Industry Excellence award for Best New Vaccine Technology & Platform at the World Vaccine Congress! 🏆#ViEAward #WVCUSA pic.twitter.com/AgtDmyIsee
— Moderna (@moderna_tx) April 20, 2022
Shorts own the trade for now, but they don’t own the future, MRNA's tech platform is validated - the potential is limitless!
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors
Actual Study Start Date : August 14, 2017
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : June 30, 2022
https://clinicaltrials.gov/ct2/show/NCT03313778
Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Moderna (MRNA – Research Report) today and set a price target of $506.00
relax$$$$$$$$$
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab
Dates
Actual Study Start Date
June 26, 2019
Estimated Primary Completion Date
August 12, 2022
Estimated Study Completion Date
August 12, 2022
https://merckoncologyclinicaltrials.com/en-us/hcp/trial/NCT03948763
Moderna's first bivalent booster vaccine candidate, mRNA-1273.211, demonstrated superior neutralizing titers compared to mRNA-1273 against all variants of concern, including Omicron; superiority was maintained for six months after booster for the Beta and Omicron variants
Tolerability and safety of the bivalent booster were consistent with authorized 50 µg mRNA-1273 booster
Moderna is evaluating an updated bivalent booster incorporating more Omicron-specific mutations (mRNA-1273.214) in a Phase 2/3 clinical study; initial data on this candidate, expected in the second quarter, will inform selection of fall 2022 booster for Northern Hemisphere
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Clinical-Update-on-Bivalent-COVID-19-Booster-Platform/default.aspx
Taipei, April 17 (CNA) Taiwan's Food and Drug Administration (FDA) authorized the use of Moderna's COVID-19 vaccine in children aged 6-11 on Sunday, setting it up to become the first COVID-19 vaccine in Taiwan available to children under the age of 12.
https://focustaiwan.tw/society/202204170008
April 14- Britain's medicines regulator said on Thursday it had approved the use of Moderna Inc's COVID-19 vaccine in children between six and 11 years, as the country bolsters itself for fighting coronavirus infections.
https://www.gov.uk/government/news/mhra-approves-the-moderna-covid-19-vaccine-spikevax-for-use-in-6-to-11-year-olds
According to Bloomberg Intelligence, the metaverse industry could be worth $800 billion by 2024 with a 13.1% compound annual growth rate (CAGR). That places the opportunity at $1.6 trillion by 2030. But that pales in comparison to an estimate by one venture capital firm, which thinks the metaverse could be worth up to $30 trillion in the next decade.
Wall Street is on board$$$$$$$
these variants continue for years!
Tencent poised to lead China's charge into the metaverse:
China is undoubtedly an attractive space to build metaverses, with its total addressable market pegged at around $8 trillion, according to a 2022 Morgan Stanley report
huge market$$$$
https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/tencent-poised-to-lead-china-s-charge-into-the-metaverse-69311462
Covid-19 Vaccines Carry Low Risk of Heart Conditions, Studies Find
Cardiac risks including myocarditis were higher following Covid-19 infection and non-Covid vaccination than after Covid vaccination
https://www.wsj.com/articles/covid-19-vaccines-carry-low-risk-of-heart-conditions-studies-find-11649716211
Jorge Gomez Joins Moderna as Chief Financial Officer :
https://stockhouse.com/news/press-releases/2022/04/11/jorge-gomez-joins-moderna-as-chief-financial-officer
Professor files Human Rights complaint in bid to get Moderna vaccine for his children
Professor knows Moderna has higher efficacy than Pfizer in the 5-11 years and fighting to get Moderna vaccine for his children.
https://ottawacitizen.com/news/local-news/professor-files-human-right-complaint-in-bid-to-get-moderna-vaccine-for-his-children
$MRNA winner
MODERNA ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1/2 STUDY WITH MRNA-1020 AND MRNA-1030 SEASONAL INFLUENZA VACCINE CANDIDATES
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participants-Dosed-in-Phase-12-Study-with-mRNA-1020-and-mRNA-1030-Seasonal-Influenza-Vaccine-Candidates/default.aspx